These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9101117)

  • 1. Direct induction of complement activation by pharmacologic activation of plasminogen.
    Schaiff WT; Eisenberg PR
    Coron Artery Dis; 1997 Jan; 8(1):9-18. PubMed ID: 9101117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator.
    Agostoni A; Gardinali M; Frangi D; Cafaro C; Conciato L; Sponzilli C; Salvioni A; Cugno M; Cicardi M
    Circulation; 1994 Dec; 90(6):2666-70. PubMed ID: 7994806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin.
    Foley JH; Walton BL; Aleman MM; O'Byrne AM; Lei V; Harrasser M; Foley KA; Wolberg AS; Conway EM
    EBioMedicine; 2016 Mar; 5():175-82. PubMed ID: 27077125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the streptokinase responsible for the endothelial injury and the platelet activation during fibrinolytic therapy?
    Kolev K; Skopál J; Nagy Z; Machovich R
    J Intern Med; 2001 May; 249(5):475-6. PubMed ID: 11350572
    [No Abstract]   [Full Text] [Related]  

  • 5. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses.
    Summaria L; Sandesara J; Yang G; Vagher JP; Caprini JA
    Thromb Haemost; 1986 Aug; 56(1):71-9. PubMed ID: 2946093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet-dependent thrombin generation after in vitro fibrinolytic treatment.
    Aronson DL; Chang P; Kessler CM
    Circulation; 1992 May; 85(5):1706-12. PubMed ID: 1533349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The search for the ideal thrombolytic agent.
    Verstraete M
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):4B-10B. PubMed ID: 2959714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolytic treatment and complement activation.
    Agostoni A; Gardinali M; Frangi D; Cugno M; Cafaro C; Conciato L; Sponzilli C; Salmoirago E
    Ann Ital Med Int; 1994; 9(3):178-9. PubMed ID: 7946896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA).
    Eisenberg PR; Miletich JP; Sobel BE; Jaffe AS
    Thromb Res; 1988 Jun; 50(5):707-17. PubMed ID: 3137687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-related differences in a clot lysis assay after adding different plasminogen activators in a plasma milieu in vitro.
    Ries M; Zenker M; Klinge J; Keuper H; Harms D
    J Pediatr Hematol Oncol; 1995 Aug; 17(3):260-4. PubMed ID: 7620925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A screening test for modified hemoglobin blood substitutes before clinical use: based on C3a complement activation in human plasma.
    Chang TM; Lister C
    Biomater Artif Cells Artif Organs; 1990; 18(5):693-701. PubMed ID: 2099226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The susceptibility of plasma to activation of fibrinolysis.
    Stief TW
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):123-5. PubMed ID: 8457639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Thrombolytics and their use].
    Alessi MC; Juhan-Vague I
    Rev Prat; 1999 Oct; 49(15):1654-8. PubMed ID: 10581996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of thrombolytic drugs.
    Verstraete M; Collen D
    J Am Coll Cardiol; 1986 Dec; 8(6 Suppl B):33B-40B. PubMed ID: 3097100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement activation by propofol and its effect during propofol anaesthesia.
    Ohmizo H; Iwama H; Sugita T
    Anaesth Intensive Care; 1999 Dec; 27(6):623-7. PubMed ID: 10631417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assays for plasma complement activation by x-ray contrast media.
    Eaton S; Tsay HM; Yost F; Tweedle MF
    Invest Radiol; 1990 Jul; 25(7):789-92. PubMed ID: 2391195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinolysis--a review.
    Kane KK
    Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abrupt complement activation and transient neutropenia in patients with acute myocardial infarction treated with streptokinase.
    Frangi D; Gardinali M; Conciato L; Cafaro C; Pozzoni L; Agostoni A
    Circulation; 1994 Jan; 89(1):76-80. PubMed ID: 7741820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.